Drug delivery

Gastroretentive Drug Delivery Systems Market Size Worth $19.7 Billion By 2028: Grand View Research, Inc.

Retrieved on: 
Tuesday, May 4, 2021
Pharmacokinetics, Drug delivery, DDS, Absorption, Market, Dosage form

b'SAN FRANCISCO, May 4, 2021 /PRNewswire/ --The global gastroretentive drug delivery systems market size is estimated to reach USD 19.7 billion by 2028, registering a CAGR of 6.4%, according to a new report by Grand View Research, Inc. Gastroretentive Drug Delivery Systems (DDSs) offer possible advantages for the drug with poor bioavailability, as their absorption is restricted to the upper Gastrointestinal Tract (GIT) and can be delivered proficiently.

Key Points: 
  • b'SAN FRANCISCO, May 4, 2021 /PRNewswire/ --The global gastroretentive drug delivery systems market size is estimated to reach USD 19.7 billion by 2028, registering a CAGR of 6.4%, according to a new report by Grand View Research, Inc. Gastroretentive Drug Delivery Systems (DDSs) offer possible advantages for the drug with poor bioavailability, as their absorption is restricted to the upper Gastrointestinal Tract (GIT) and can be delivered proficiently.
  • The controlled and systematic DDS minimizes the chances of medicine overexposure at the diseased site.
  • Hence, various advantages associated with gastroretentive DDSs are expected to foster the overall market progression.\nThe DDS sustains the release of drugs and avails local therapy in the small intestine and stomach.
  • Hence, the above-mentioned factors are predicted to augment market expansion.\nGrand View Research has segmented the global gastroretentive drug delivery systems market on the basis of type, dosage form, distribution channel, and region:\n'

Global Drug Delivery in Central Nervous System Diseases 2021 Research Report - Technologies, Markets & Companies - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 27, 2021
Pharmaceutical, Health, Medical devices, Health sciences, Life sciences, Branches of biology, Medication, Pharmaceutical industry, Drug delivery, Drug, Neuroscience, Blood-Spinal Cord Barrier, Nanoparticles for drug delivery to the brain

b'The "Drug Delivery in Central Nervous System Diseases - Technologies, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com\'s offering.\nThe delivery of drugs to central nervous system (CNS) is a challenge in the treatment of neurological disorders.

Key Points: 
  • b'The "Drug Delivery in Central Nervous System Diseases - Technologies, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com\'s offering.\nThe delivery of drugs to central nervous system (CNS) is a challenge in the treatment of neurological disorders.
  • The market for CNS drug delivery technologies is directly linked to the CNS drug market.
  • Unmet needs for further development in CNS drug delivery technologies are identified according to the important methods of delivery of therapeutic substances to the CNS.
  • These include pharmaceutical companies that develop CNS drugs and biotechnology companies that provide technologies for drug delivery.

Drug Delivery in Cancer 2021: Technologies, Markets & 238 Company Profiles - ResearchAndMarkets.com

Retrieved on: 
Friday, April 23, 2021
Pharmaceutical, Health, Oncology, Medicine, Clinical medicine, Medical specialties, Immunology, Cancer immunotherapy, Immunotherapy, Virotherapy, Cancer, Drug delivery, Treatment of cancer, Monoclonal antibody, CancerVax

b'The "Drug Delivery in Cancer - Technologies, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com\'s offering.\nDrug delivery remains a challenge in the management of cancer.

Key Points: 
  • b'The "Drug Delivery in Cancer - Technologies, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com\'s offering.\nDrug delivery remains a challenge in the management of cancer.
  • Approximately 12.5 million new cases of cancer are being diagnosed worldwide each year and considerable research is in progress for drug discovery for cancer.
  • Cancer drug delivery is no longer simply wrapping up cancer drugs in a new formulations for different routes of delivery.
  • Important methods of immunotherapy in cancer involve the use of cytokines, monoclonal antibodies, cancer vaccines and immunogene therapy.\nSeveral innovative methods of drug delivery are used in cancer.

IntelGenx Announces Intention to Amend Convertible Unsecured Promissory Notes

Retrieved on: 
Friday, April 9, 2021
Medicine, Health sciences, Routes of administration, Transdermal, Drug delivery, Health

The proposed amendments are subject to approval of the TSX Venture Exchange and holders holding a majority of the aggregate outstanding principal amount of the Notes.

Key Points: 
  • The proposed amendments are subject to approval of the TSX Venture Exchange and holders holding a majority of the aggregate outstanding principal amount of the Notes.
  • An aggregate principal amount of U.S.$1,600,000 of Notes is outstanding as of the date hereof.
  • IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.
  • IntelGenxs superior film technologies, including VersaFilm, DisinteQ, VetaFilm and transdermal VevaDerm, allow for next generation pharmaceutical products that address unmet medical needs.

Kindeva Drug Delivery and Cambridge Healthcare Innovations Limited to Collaborate on Development of Novel Dry-Powder Inhaler Product

Retrieved on: 
Tuesday, April 6, 2021
Health, Medical devices, Diabetes, Other Health, General Health, Pharmaceutical, Biotechnology, Health sciences, Medicine, Clinical medicine, Dosage forms, Routes of administration, Medical equipment, Respiratory therapy, Asthma, Transdermal, Dry-powder inhaler, Drug delivery, DPI, Kindeva Drug Delivery, Cambridge Healthcare Innovations

Kindeva Drug Delivery L.P. (Kindeva) and Cambridge Healthcare Innovations Limited (CHI) have entered into a collaboration to develop and commercialize CHIs eolus dry-powder inhaler (DPI) platform technology.

Key Points: 
  • Kindeva Drug Delivery L.P. (Kindeva) and Cambridge Healthcare Innovations Limited (CHI) have entered into a collaboration to develop and commercialize CHIs eolus dry-powder inhaler (DPI) platform technology.
  • To accelerate platform and product development, Kindeva and CHI will evaluate a range of drugs for the eolus platform.
  • Under the agreement, Kindeva will lead business development and product development activities, including toxicology, process development, and clinical design, while CHI leads technology and device development.
  • Kindeva focuses on complex drug programs, and its current offering spans inhalation drug delivery, transdermal drug delivery, microstructured transdermal systems (microneedles), and connected drug delivery.

India Drug Delivery Devices Market Forecast & Opportunities, FY2026: Devices (Syringe, Inhaler, Nebulizer, Transdermal Patch) & Route of Administration (Oral Drug Delivery, Injectable Drug Delivery) - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 23, 2021
Pharmaceutical, Health, Medical devices, Health sciences, Pharmacology, Medicine, Routes of administration, Dosage forms, Medical equipment, Pharmacokinetics, Transdermal patch, Transdermal, Route of administration, Drug delivery, Nebulizer

The "India Drug Delivery Devices Market, By Devices (Syringe, Inhaler, Nebulizer, Transdermal Patch), By Route of Administration (Oral Drug Delivery, Injectable Drug Delivery, Others), By Patient Care Setting, By Application, By Region, By Region, Forecast & Opportunities, FY2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "India Drug Delivery Devices Market, By Devices (Syringe, Inhaler, Nebulizer, Transdermal Patch), By Route of Administration (Oral Drug Delivery, Injectable Drug Delivery, Others), By Patient Care Setting, By Application, By Region, By Region, Forecast & Opportunities, FY2026" report has been added to ResearchAndMarkets.com's offering.
  • The Indian Drug Delivery Devices Market was valued at around USD564 million in FY2020 and is expected to grow at a steady CAGR of 8.05% during the forecast period.
  • The Indian Drug Delivery Devices Market is driven by growing use of drug delivery systems in healthcare facilities.
  • The Indian Drug Delivery Devices Market is segmented based on devices, route of administration, patient care setting, application, company, and region.

Eisai Begins Construction of Its New Injection/Research Building at Kawashima Industrial Park in Japan

Retrieved on: 
Monday, March 22, 2021
Health sciences, Pharmacy, Life sciences, Health care, Eisai, Pharmaceutics, Drug delivery, Pharmaceutical industry, Formulation

The current research building at Kawashima Industrial Park has served as a base for formulation research since its completion in 1980.

Key Points: 
  • The current research building at Kawashima Industrial Park has served as a base for formulation research since its completion in 1980.
  • Most of these new modality formulations are injectable; thus the utilization of enhanced injection formulation technologies and drug delivery systems (DDSs) is essential.
  • In addition, Eisai will install an injection manufacturing facility that meets GMP* requirements, and is aiming for the in-house manufacturing of investigational injection drugs.
  • The Kawashima Industrial Park is Eisai's global pharmaceutical manufacturing base, at which Eisai has made a comprehensive framework comprising all steps from formulation research to formulation manufacturing.

IntelGenx to Report Fourth Quarter and Full-Year 2020 Financial Results on March 25, 2021 – Conference Call to Follow

Retrieved on: 
Thursday, March 18, 2021
Health sciences, Life sciences, Pharmaceutical industry, Pharmaceutical sciences, Medication, Drug delivery

IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.

Key Points: 
  • IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.
  • IntelGenxs superior film technologies, including VersaFilm, DisinteQ, VetaFilm and transdermal VevaDerm, allow for next generation pharmaceutical products that address unmet medical needs.
  • IntelGenxs innovative product pipeline offers significant benefits to patients and physicians for many therapeutic conditions.
  • This document may contain forward-looking information about IntelGenx' operating results and business prospects that involve substantial risks and uncertainties.

Vesigen Therapeutics Announces Issuance of U.S. Patent for Broad Applications of ARMMs Technology

Retrieved on: 
Tuesday, March 16, 2021
Branches of biology, Biology, Vesicles, Cell biology, Molecular biology, Medical diagnosis, Microvesicles, Nanotechnology, Vesicle, Extracellular vesicle, Cell–cell fusogens, Drug delivery

This patent, exclusively licensed to Vesigen from Harvard University, broadly covers many of the drug delivery features of any ARRDC1-mediated microvesicles (ARMMs).

Key Points: 
  • This patent, exclusively licensed to Vesigen from Harvard University, broadly covers many of the drug delivery features of any ARRDC1-mediated microvesicles (ARMMs).
  • Vesigen is engineering ARMMs particles to improve this natural mechanism for more effective targeted delivery of therapeutic agents.
  • Vesigen Therapeutics is a biotechnology company advancing groundbreaking therapies directed to intracellular targets using a fusogenic extracellular vesicle delivery technology.
  • Vesigen will advance the ARMMs platform to develop innovative medicines for patients through an exclusive license agreement with Harvard University.

PLx Pharma Inc. to Present at the Oppenheimer 31st Annual Healthcare Conference

Retrieved on: 
Thursday, March 11, 2021
Pharmacology, Health sciences, Drugs, Hepatotoxins, Dosage forms, Aspirin, Commercialization of traditional medicines, Pharma, Drug delivery, Modified-release dosage

It also reduces the risk of stomach erosions and ulcers, as compared to immediate-release aspirin, common in an acute setting.

Key Points: 
  • It also reduces the risk of stomach erosions and ulcers, as compared to immediate-release aspirin, common in an acute setting.
  • PLx Pharma Inc. is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard drug delivery platform to provide more effective and safer products.
  • The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the gastrointestinal (GI) tract.
  • To learn more aboutPLx Pharma Inc. and its pipeline, pleasevisit www.plxpharma.com .